Sign In
Buy VIVO
$3.90
+0.170 (+4.56%)
At Close: Aug 04, 2026
Boston Scientific (BSX) Q1 Earnings Top, 2022 Revenue View Up
03:37pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in the legacy business from the pandemic mayhem.
Chemed's (CHE) Q1 Earnings Top Estimates, Margins Increase
03:01pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
In Q1, Chemed's (CHE) VITAS revenue decline was primarily the result of a 4.1% decline in days of care.
Exact Sciences (EXAS) Q1 Earnings Top Estimates, Sales View Up
02:25pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Robust performances by the Screening and Precision Oncology segments drove Exact Sciences' (EXAS) first-quarter top line.
Charles River (CRL) to Report Q1 Earnings: What's in Store?
02:24pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Robust global demand for the research model and multiple initiatives to expedite the discovery process are likely to have contributed to Charles River's (CRL) first-quarter results.
Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?
01:01pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Robust demand in the global dental market with the steady improvement in patient traffic is likely to have contributed to Henry Schein's (HSIC) Q1 performance.
Ecolab's (ECL) Q1 Earnings in Line, Revenues Beat Estimates
04:34pm, Tuesday, 26'th Apr 2022 Zacks Investment Research
Ecolab's (ECL) robust performance across all of its segments drives its Q1 sales despite business challenges.
Catalent (CTLT) to Report Q3 Earnings: What's in the Cards?
04:55pm, Monday, 25'th Apr 2022 Zacks Investment Research
Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.
Bio-Rad (BIO) to Report Q1 Earnings: What's in the Cards?
01:02pm, Monday, 25'th Apr 2022 Zacks Investment Research
Robust uptake of dPCR products and a rebound in routine testing are likely to have contributed to Bio-Rad's (BIO) first-quarter top line.
Fulgent Genetics (FLGT) to Post Q1 Earnings: What's in Store?
12:38pm, Monday, 25'th Apr 2022 Zacks Investment Research
Strategic investments and expanding operations in China are likely to have contributed to Fulgent Genetics' (FLGT) first-quarter performance.
LabCorp (LH) to Report Q1 Earnings: What's in the Cards?
03:22pm, Friday, 22'nd Apr 2022 Zacks Investment Research
Robust base business growth and notable launches are likely to have contributed to LabCorp's (LH) Q1 performance.
Abiomed (ABMD) to Report Q4 Earnings: What's in the Cards?
03:16pm, Friday, 22'nd Apr 2022 Zacks Investment Research
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven Q4 sales.
Hologic (HOLX) to Report Q2 Earnings: What's in the Cards?
01:14pm, Thursday, 21'st Apr 2022 Zacks Investment Research
Strength in Diagnostics and GYN Surgical businesses is likely to have contributed to Hologic's (HOLX) fiscal second-quarter revenues.
Align Technology (ALGN) to Post Q1 Earnings: What's in Store?
01:05pm, Thursday, 21'st Apr 2022 Zacks Investment Research
Robust demand for iTero scanners and increasing Invisalign case submissions are expected to have contributed to Align Technology's (ALGN) Q1 performance.
What's in Store for Boston Scientific (BSX) in Q1 Earnings?
03:00pm, Wednesday, 20'th Apr 2022 Zacks Investment Research
Given an innovative pipeline, expansion into faster growth markets, globalization efforts and enhanced digital capabilities, Boston Scientific (BSX) is well-positioned to register strong first quarter
Ecolab (ECL) to Report Q1 Earnings: What's in the Offing?
02:53pm, Wednesday, 20'th Apr 2022 Zacks Investment Research
Ecolab's (ECL) first-quarter results are likely to reflect continued strength across its business segments.
